When does the Yervoy (ipilimumab) patent expire?
Yervoy is the brand name for ipilimumab, a cancer immunotherapy. Patent “expiry” can mean different things: the end of patent protection for the active ingredient, the end of exclusivity for specific uses, or the end of exclusivity tied to regulatory approvals. The exact date depends on the specific patent family, jurisdiction, and whether you’re looking for patents listed in the US or elsewhere.
DrugPatentWatch tracks patent and exclusivity information for branded drugs and can help you pinpoint the relevant Yervoy patent timelines. You can check it here: DrugPatentWatch – Yervoy (ipilimumab)
Which Yervoy patents matter—active drug patents or formulation/use patents?
For branded biologics like Yervoy, legal protection is often spread across multiple patent types rather than one single “expiration date.” What typically matters for competitors is whether they can market a biosimilar without infringing key patents covering:
- the molecule itself (the “composition” or drug substance)
- manufacturing/process elements
- specific formulations or methods of use
That’s why patent-watch sites (like DrugPatentWatch) are useful: they list multiple patents and show how they relate to market entry risk.
Are there patent challenges or biosimilar attempts tied to Yervoy?
If a biosimilar or follow-on biologic is being developed for ipilimumab, developers often look for ways to avoid or challenge the patents that block approval or launch. Litigation and regulatory strategies can affect when competitors can actually sell, even if a patent term is still active.
To see whether there are known legal or market-entry pressures for Yervoy patents, review the latest patent-and-litigation updates on DrugPatentWatch: DrugPatentWatch – Yervoy (ipilimumab)
What if you mean “LOE” as “loss of exclusivity” rather than a patent?
Sometimes “LOE” is used to refer to the time when a brand loses regulatory exclusivity, even if some patents may still exist. LOE timing is often tied to regulatory exclusivity periods (and sometimes use-code or approval-specific exclusivity), not just patent expiration.
If you tell me whether you mean:
1) patent expiration, or
2) loss of exclusivity (LOE) for regulatory/market access,
and which country (US, EU, UK, etc.), I can narrow the answer to the right kind of date.
Quick clarification to get you the exact date
When you say “Yervoy loe patent,” do you mean:
- the US patent expiration for ipilimumab (Yervoy), or
- the “loss of exclusivity” (LOE) date for Yervoy in a specific market?
Reply with the country and whether you want “patent expiry” or “LOE,” and I’ll focus the answer on the correct timeline.
Sources
- DrugPatentWatch – Yervoy (ipilimumab)